We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

2 top FTSE 100 shares to buy right now

Here are two FTSE 100 shares that operate in booming sectors that I think are excellent growth options for my long-term portfolio right now.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

The FTSE 100 index is trading steadily at its highest levels since the pandemic. It’s up 3.3% in the last month, dispelling my concerns of a potential market crash after the Evergrande collapse in China. I think it’s a great time to catch some excellent shares on their way up and here are the three UK shares I’m watching closely now.

Pharma drama

Over the last decade, the pharma sector has been under scrutiny for hiking the prices of life-saving drugs. Distrust of big pharma is at an all-time high in some quarters with the pandemic fuelling existing concerns over the cost of medication. I think FTSE 100 company Hikma Pharmaceuticals (LSE:HIK) addresses this issue.

Should you buy Glencore Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

The pharma company specialises in low-cost, generic versions of popular medication. This is an area that I think shows a lot of promise. Although R&D in the field of medicine is paramount, I think the ageing British (and global) population will benefit from low-cost treatment options as well.

From a potential investor’s perspective, a return of -4.3% in 2021 might seem like a red flag, but when I look at the five-year graph, Hikma shares have increased steadily, offering a robust 51% return. The first-half 2021 report makes for good reading. Revenue was up 7% to US$1.2bn and operating profits were up 10% at $326mn.

But, Hikma shares have had a turbulent run in the market over the last five years. This tells me that shareholder confidence isn’t great. And there are concerns surrounding inflated revenue in the injectables division of the company, which received a temporary sales boost during the pandemic. This is expected to drop in the coming months, which could dent revenue.

However, the company looks like a good long-term investment for my portfolio and operates in a sector that I think will remain crucial. It’s on my FTSE 100 shares to buy list for November.

Mining share up 125% in a year

Glencore (LSE:GLEN) is the world’s largest commodity trader with large mining operations as well. The company has 26 coal mines around the world and is a major producer of cobalt, copper and Nickel — all crucial components in electric vehicle (EV) manufacture.

Commodities prices are rising globally and I think Glencore stands to gain a lot from this. When I look at its market performance, the whopping 125% returns in 12-months are impressive. And they come with a 2.4% dividend yield as well. Its shares are currently on a small downtrend, falling 2.7% in the last week. I think its current price of 253p is an excellent entry point for my portfolio.

The company’s 2021 half-year report showed a 32% increase in revenue to US$93.8bn, a 4% increase in total assets to $122.4bn and a 33% decrease in net debt, which stood at $10.6bn.

The mining company is also well-positioned to cash in on the coal shortage in Asia. But over the long term, commodities prices could normalise, which will cut into Glencore’s profits. And there are ethical concerns and the environmental impact of the mining sector as a whole (especially coal), which Glencore will have to address in the coming years. But I think the surge in construction after the pandemic and the increase in production in EVs sets up Glencore for sustained returns, which is why it also makes my FTSE 100 buy list.

Suraj Radhakrishnan has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female couple boarding their plane at the airport to go on holiday.
Investing Articles

Can the Rolls-Royce share price reach £15.97 by the end of August?

The Rolls-Royce share price has had a solid run in the last year. Muhammad Cheema takes a look at whether…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 1,200% in 5 years, here’s why Nvidia could still be a brilliant value stock

An exciting new announcement that could reshape the PC industry has just pushed Nvidia stock... well, just about nowhere really.

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

How investing £4.50 a day could set you on the way to a £1,505 monthly second income

How can UK stocks with high dividend yields help investors earn a meaningful second income from the price of a…

Read more »

Investing Articles

Up 103% with a P/E of 261 — is this FTSE 100 stock still worth buying?

One FTSE 100 stock is quietly moving higher while most investors are still looking elsewhere — is the market missing…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

The smart money thinks AI stocks look risky — but is there still a chance to buy?

According to fund managers, the AI trade is getting crowded. But they still seem to think it’s the place to…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Barclays shares are 11% below their 52-week high. Could they be a bit of a bargain to consider?

Overpriced or one of the FTSE 100’s hidden gems? James Beard takes a closer look at how the market is…

Read more »

Stack of one pound coins falling over
Investing Articles

Down 65% but yielding 6.7% – is this beaten-down UK stock now a generational bargain?

Harvey Jones says this UK stock is one of the worst FTSE 100 performers but there are sound reasons to…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is this FTSE stock really 46% undervalued?

Analysts reckon this FTSE stock should be worth nearly 50% more. James Beard considers why there’s so much positivity surrounding…

Read more »